Evaluating whether to purchase Upstream Bio (NASDAQ: UPB) requires careful consideration of clinical-stage biotechnology risks, impending trial data readouts, and capital burn rates. To tailor this investment context: What is your total portfolio risk tolerance, and what percentage of your assets do you allocate to speculative biotech equities?